Markets:

Overview

News

Currencies

International

Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

18.95 -1.57 (-7.65%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jul 10, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

35 36 Next >

2 Beaten-Down Stocks That Still Aren't Worth Buying ↗

July 11, 2026

Your hard-earned money would be better spent elsewhere.

Via The Motley Fool

Topics Artificial Intelligence

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 30, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Announces FDA Acceptance of sNDAs for AMONDYS 45® and VYONDYS 53®

June 30, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion

June 03, 2026

Via Investor Brand Network

Sarepta Therapeutics (NASDAQ:SRPT) Q1 2026 Earnings Beat Overshadowed by Revenue Dip ↗

May 06, 2026

Via Chartmill

Topics Earnings

NetworkNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on Advanced Drug Delivery and Platform-Based Biotech Innovation

June 03, 2026

Via Investor Brand Network

Topics Artificial Intelligence Intellectual Property

Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion

June 03, 2026

From BioMedWire

Via GlobeNewswire

Sarepta Therapeutics to Participate in Upcoming Investor Conferences

June 01, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

My Top 3 Biotech Stocks for May 2026 ↗

May 20, 2026

As FDA activity accelerates and big pharma searches for its next generation of blockbuster drugs, select biotech companies are beginning to stand out from the crowd.

Via The Motley Fool

Topics Artificial Intelligence Intellectual Property

Sarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference

May 13, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta (SRPT) Q1 2026 Earnings Transcript ↗

May 06, 2026

Sarepta (SRPT) Q1 2026 Earnings Transcript

Via The Motley Fool

Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments

May 06, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Therapeutics to Announce First Quarter 2026 Financial Results

April 22, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial Highlighting Biotech’s Shift Toward Science-Driven Asset Valuation

April 20, 2026

Via Investor Brand Network

Topics Artificial Intelligence

When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech

April 20, 2026

Via Investor Brand Network

When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech

April 20, 2026

From BioMedWire

Via GlobeNewswire

Ultragenyx Vaults Toward Commercialization as FDA Accepts Landmark Gene Therapy BLA

April 02, 2026

In a pivotal moment for the rare disease community and the biotechnology sector, Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) has reached a critical regulatory milestone. The U.S. Food and Drug...

Via MarketMinute

Topics Intellectual Property Lawsuit

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 31, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

Biotech Defies Gravity: Sarepta and Corcept Lead Midday Healthcare Rally Amidst Market Volatility

March 31, 2026

In a trading session characterized by sharp declines across the technology and industrial sectors, the healthcare industry emerged as a resilient fortress on March 31, 2026. While the broader S&P 500...

Via MarketMinute

Topics Economy Intellectual Property Stocks

Sarepta's RNA Renaissance: 35% Surge as siRNA Breakthrough Silences Skeptics

March 26, 2026

CAMBRIDGE, MA — March 26, 2026 — Shares of Sarepta Therapeutics (NASDAQ: SRPT) skyrocketed 35% in early trading today, reaching levels not seen since the company’s early days in Duchenne Muscular...

Via MarketMinute

Sarepta Therapeutics (SRPT) Stock Surges 34.98% on Breakthrough Clinical Data

March 26, 2026

CAMBRIDGE, MA — March 26, 2026 — Shares of Sarepta Therapeutics (NASDAQ:SRPT) skyrocketed 34.98% in heavy trading today, marking the biotech giant's most explosive single-day gain in over two years....

Via MarketMinute

The RNA Renaissance: Decoding Sarepta Therapeutics’ 34% Surge and the Future of Precision Medicine

March 26, 2026

On March 25, 2026, the biotechnology sector witnessed a tectonic shift as Sarepta Therapeutics (NASDAQ: SRPT) saw its share price skyrocket by 34% in a single trading session. This dramatic surge—the...

Via Finterra

Topics Retirement

Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗

March 25, 2026

Via Chartmill

Wednesday's session: top gainers and losers ↗

March 25, 2026

Via Chartmill

Which stocks are gapping on Wednesday? ↗

March 25, 2026

Via Chartmill

Sarepta Therapeutics (SRPT) at a Crossroads: A 2026 Deep Dive into the Future of Genetic Medicine

March 25, 2026

As of March 25, 2026, Sarepta Therapeutics (NASDAQ: SRPT) stands at a pivotal, albeit bruising, crossroads in the history of genetic medicine. Once the darling of the biotechnology sector for its...

Via Finterra

Topics Economy Intellectual Property Retirement

Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1

March 25, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1

March 24, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

2 Beaten-Down Stocks That Still Aren't Worth Buying ↗

March 21, 2026

These stocks aren't nearly as cheap as they look.

Via The Motley Fool

Topics Cannabis

Sarepta Provides Regulatory Update on AMONDYS 45® and VYONDYS 53®

March 19, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

35 36 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.